SCHEMBL25007300

SCHEMBL25007300

O=C(c1cccc(F)c1)C(F)(F)c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
ACHE P22303 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 1/20 0.46
PARP1 P09874 2/20 0.45
RAB9A P51151 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GRM5 P41594 3/20 0.44
GRIN2B Q13224 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KCNN4 O15554 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30222651 1.00 CES2 (0.47) CES2CES1ACHESMN1; SMN2HTT
SCHEMBL25007317 0.86 CES1 (0.48) CES2CES1ACHEPARP1RAB9A
SCHEMBL9771667 0.80 ACHE (0.42) ACHESMN1; SMN2HTTRAB9AMEN1
Hydrochloric Acid SCHEMBL9315815 0.79 ACHE (0.41) ACHESMN1; SMN2HTTRAB9AMEN1
SCHEMBL30222811 0.79 SMN1; SMN2 (0.49) SMN1; SMN2HTTMEN1KMT2AGRM5
SCHEMBL25007318 0.78 CYP19A1 (0.55) SMN1; SMN2RAB9AMEN1KMT2AGRM5
SCHEMBL29791495 0.77 ACHE (0.58) CES1ACHESMN1; SMN2HTTPARP1
SCHEMBL111125 0.77 ACHE (0.58) CES1ACHESMN1; SMN2HTTPARP1
SCHEMBL30166168 0.76 CES1 (0.65) CES2CES1ACHESMN1; SMN2PARP1
SCHEMBL1273634 0.76 CES1 (0.65) CES2CES1ACHESMN1; SMN2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. 2024-12-05 US disclosed
EP-4380920-A1 INHIBITORS FOR CORONAVIRUSES Cocrystal Pharma, Inc. (US) 2024-06-12 EP disclosed
CN-118103351-A Coronavirus inhibitors 共晶制药公司 2024-05-28 CN disclosed
WO-2023014758-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. (US) 2023-02-09 WO disclosed
WO-2023014758-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. (US) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES ACE, ACE2, SARS1 CES2 1219/4885CES1 271/4885ACHE 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.